Journal of Clinical Oncology
Articles in this Issue
Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with previously treated advanced pancreatic ductal adenocarcinoma (PDAC).
4208 Background: The prognosis for patients with advanced PDAC after failure of first-line therapy remains dismal with lim...
Real-world outcomes of biomarker-guided multidisciplinary management in localized and metastatic gastric cancer.
e16060 Background: Gastric cancer (GC) is a biologically heterogeneous disease with limited prognosis, particularly in adv...
Olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: Meta-analysis of efficacy and safety outcomes.
e18503 Background: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is an aggressive B-cell maligna...
Beyond translation: Leveraging interpreter expertise to enhance clinician training and language equity in pediatric oncology.
10025 Background: Medical interpreters play a critical role in pediatric oncology beyond translation by guiding conversati...
Efficacy and tolerability of duvelisib in relapsed/refractory peripheral T-cell lymphoma: A multicenter real-world analysis.
7067 Background: Relapsed/refractory (R/R) peripheral T-cell lymphomas (PTCL) are a rare group of non-Hodgkin lymphomas wi...
Epstein-Barr virus reactivation and post-transplant lymphoproliferative disorder following letermovir prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A systematic review and meta-analysis.
e18569 Background: Letermovir is a cytomegalovirus (CMV) terminase complex inhibitor that significantly reduces clinically...
Tumor-informed molecular monitoring using patient-specific PCR assays and oncologist decision-support software.
e15082 Background: Tumor-informed molecular monitoring leveraging patient specific somatic mutations enables highly sensit...
Specialist referral patterns and relationship to outcomes in patients with hepatocellular carcinoma.
e16242 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of c...
Phase 1b/2 study of pembrolizumab plus lenvatinib or pembrolizumab coformulated with vibostolimab in participants (pts) with metastatic neuroendocrine prostate cancer (NEPC): KEYNOTE-365 cohorts F and H.
5055 Background: Effective therapy for NEPC is an unmet need due to poor prognosis and no established standard of care. Th...
Comparative efficacy and safety of novel agents versus standard chemotherapy in first-line (1L) locally advanced or metastatic triple-negative breast cancer (TNBC): A systematic review and network meta-analyses.
e13124 Background: Survival outcomes for patients with advanced TNBC remain poor. Several novel agents, including antibody...
Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.
7075 Background: APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) mutational signatures are uncom...
A phase 1b/2 study of mirdametinib in combination with sirolimus for patients with RAS-mutated relapsed/refractory multiple myeloma.
TPS7582 Background: Relapsed and refractory multiple myeloma (RRMM) remains a significant therapeutic challenge, particula...
Cardiovascular toxicity across epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in <i>EGFR</i> -mutated non–small cell lung cancer: A population-based retrospective cohort study.
12155 Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the therapeutic backbone f...
Racial and payer-based disparities in inpatient resource utilization and mortality among patients hospitalized with head and neck cancer in the United States, 2018 to 2022.
11099 Background: Inpatient hospitalizations for head and neck cancer (HNC) reflect advanced disease, treatment-related co...
Sex differences in thyroid cancer in Hanoi: Incidence trends and projections to 2045 from the Hanoi Cancer Registry.
e18080 Background: Thyroid cancer epidemiology has shown distinct sex-related differences, with women historically having...
Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) in combination with adagrasib in <i>KRAS</i> G12C mutated (mut) advanced solid tumors: Preliminary results from the FIT-001 phase 1 first-in-human trial.
3078 Background: Clinical response to RAS inhibitors (RASi) is often limited by inherent/adaptive resistance mediated by p...
The role of sarcopenia and adiposity in prognosis of pleural mesothelioma: A CT-based analysis.
8053 Background: Pleural mesothelioma (PM) is a rare malignancy associated with asbestos exposure and characterized by an...
Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial.
105 Background: The ESOPEC trial showed that perioperative chemotherapy improved survival compared with preoperative chemo...
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab.
TPS4642 Background: Although first-line (1L) EV + pembrolizumab has improved outcomes for patients with la/mUC, most exper...
FLT3 inhibitors in acute myeloid leukemia: A network meta-analysis of phase III trials.
e18505 Background: FLT3 inhibitors improve outcomes in FLT3-mutated acute myeloid leukemia (AML); however, no head-to-head...
Distinct genomic and microenvironmental profiles of brain metastases in renal cell carcinoma: Insights into hypoxia-driven adaptation and therapeutic vulnerabilities.
2033 Background: Brain metastases (BM) in renal cell carcinoma (RCC) are associated with poor prognosis and may exhibit un...
Divergent transcriptomic signatures and microenvironmental markers of <i>KRAS</i> and <i>BRAF</i> mutations in colorectal cancer: A multi-omics integrative analysis.
3668 Background: KRAS and BRAF mutations are critical drivers...
Trends and disparities in esophageal cancer mortality in the United States, 1999-2023.
e16102 Background: Esophageal cancer remains a significant cause of cancer mortality in the United States. While overall t...
ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer.
3096 Background: Radium-223 dichloride is an alpha particle emitting radiopharmaceutical that mimics calcium and localizes...
Phase 1, multi-center clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of PQ203, a first-in-class peptide drug conjugate targeting SORT1 in patients with advanced solid tumor malignancies (NCT07190469).
TPS3171 Background: Antibody–drug conjugates (ADCs) have improved outcomes in several refractory cancers by enabling the t...